Imaging Bone Morphogenetic Protein 7 Induced Cell Cycle Arrest in Experimental Gliomas  by Klose, Anke et al.
Imaging Bone Morphogenetic
Protein 7 Induced Cell Cycle
Arrest in Experimental Gliomas1,2
Anke Klose*, Yannic Waerzeggers*,
Parisa Monfared*, Slobodan Vukicevic†,
Eric L. Kaijzel‡, Alexandra Winkeler*,
Claudia Wickenhauser‡, Clemens W. G. M. Löwik§
and Andreas H. Jacobs*
*European Institute for Molecular Imaging, University of
Münster, Germany and MPI for Neurological Research,
Cologne, Germany; †Department of Anatomy, School
of Medicine, Zagreb, Croatia; ‡Department of Pathology,
Faculty of Medicine of the University of Leipzig, Leipzig,
Germany; §Department of Endocrinology and Metabolic
Diseases, Leiden University Medical Center, Leiden,
The Netherlands
Abstract
Bone morphogenetic protein 7 (BMP-7) belongs to the superfamily of transforming growth factor β–like cytokines,
which can act either as tumor suppressors or as tumor promoters depending on cell type and differentiation. Our
investigations focused on analyzing the effects of BMP-7 during glioma cell proliferation in vitro and in vivo. BMP-7
treatment decreased the proliferation of Gli36ΔEGFR-LITG glioma cells up to 50% through a cell cycle arrest in the G1
phase but not by induction of apoptosis. This effect was mediated by the modulation of the expression and phos-
phorylation of cyclin-dependent kinase 2, cyclin-dependent kinase inhibitor p21, and downstream retinoblastoma
protein. Furthermore, in vivo optical imaging of luciferase activity of Gli36ΔEGFR-LITG cells implanted intracranially
into nude mice in the presence or absence of BMP-7 treatment corroborated the antiproliferative effects of this
cytokine. This report clearly underlines the tumor-suppressive role of BMP-7 in glioma-derived cells. Taken together,
our results indicate that manipulating the BMP/transforming growth factor β signaling cascade may serve as a new
strategy for imaging-guided molecular-targeted therapy of malignant gliomas.
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Introduction
Glioblastoma multiforme (GBM) is the most aggressive primary glial
tumor of the brain, with an average life expectancy of 1 year or less [1].
Therefore, therapeutic approaches are needed to treat tumors more ef-
fectively by targeting molecular signal transduction pathways involved
in cancer progression directly. Deregulation of growth factor or growth
factor receptor expression is one of the characteristic features of GBM.
One pathway frequently affected during gliomagenesis is the transform-
ing growth factor β (TGF-β) signaling pathway [2,3]. This pathway is
often referred to as a double-edged sword because the tumor-suppressive
activity of TGF-β can switch to be a stimulator of malignant progres-
sion [4–6].
Bone morphogenetic proteins (BMPs) are cytokines belonging to the
TGF-β superfamily, whose members reveal a variety of biologic func-
tions such as proliferation and apoptosis [7,8]. The biologic effects of
BMPs as well as of TGF-β are mediated by cytosolic Smad-dependent
and several Smad-independent intracellular signaling pathways [5]. To
signal through the canonical BMP pathway, dimeric cytokines bind to
heterotetrameric receptor complexes on the cell surface composed of
type I and II receptor homodimers. Activated type I receptors initiate
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downstream signaling by phosphorylation of receptor-regulated Smad
proteins (R-Smads), which form complexes with Smad-4 (Co-Smad)
to translocate into the nucleus and initiate target gene transcription.
Heteromeric combination of TGF-β superfamily receptors, R-Smad–
Co-Smad complex formation, and regulation by inhibitory Smads
point out at the complexity of the TGF-β superfamily signaling [9,10].
TGF-β, BMPs as well as the other members of this superfamily, is a
potent inhibitor of growth, such as epithelial and endothelial cell
growth, but reveals mitogenic properties in mesenchymal-derived cells.
Two events are known to mediate the TGF-β–induced growth arrest
in mid- and late-G1 phases of the cell cycle: inactivation of cyclin-
dependent kinases (Cdks) and down-regulation of c-myc [11,12].
The transition from G1 to S phase in the mammalian cell cycle is co-
operatively regulated by cyclins, Cdks, and Cdk inhibitors (CdkIs). The
first class of CdkIs that specifically inhibit Cdk4 and Cdk6 includes
the INK4A proteins (p16INK4A, p15INK4B, p18INK4C, and p19INK4D),
whereas members of the Cip/Kip family of inhibitors (p21Cip1/Waf1,
p27Kip1, and p57Kip2) reveal a broader inhibition spectrum. Progression
in the cell cycle involves phosphorylation of the retinoblastoma protein
(Rb) tumor-suppressor gene product pRb [13]. Similar to TGF-β,
BMPs have also been shown to influence cell proliferation and apopto-
sis. Suppression of tumor formation in skin by induction of apoptosis
was reported on the overexpression of BMP-6 [14]; similarly, the anti-
tumor effect of BMP-5, -6, and -7 in human myeloma cells was also
mediated by the induced apoptosis [15]. BMP signaling has been dem-
onstrated to be growth suppressive in colon cancer cells [16]. Cell cycle
arrest, induced by upregulation of p21Cip1 and p27Kip1, was reported
for BMP-7–treated thyroid carcinoma cells [17]. Growth inhibition of
BMP-2–treated breast carcinoma cells revealed to be a consequence of
p21Cip1/Waf1 upregulation, inhibition of Cdk2, and hypophosphoryla-
tion of pRb [18]. The same results were obtained by Miyazaki et al.
[19] after administration of BMP-7 in vitro and overexpression of
constitutively active Alk-6 receptor in androgen-insensitive prostate
cancer cells in vivo. BMP-7 also counteracted breast cancer growth at
the primary site and in bone metastasis in vivo [20]. Already in 1996,
Yamada et al. [21] demonstrated the progressive expression of Alk-6 in
malignant glioma tumors. More recently, it has been shown that BMPs
promote differentiation, thereby depleting the pool of brain tumor–
initiating cells [22,23].
In the following study, we focused on elucidating how BMP-7 in-
fluences glioma cell growth in vitro and analyzed the underlying mo-
lecular mechanisms. In addition, by optical imaging, we could monitor
and confirm in vivo antiproliferative effects of BMP-7 in experimental
gliomas. Our results presented herein provide evidence for the striking
role of BMP-7 in regulatory processes of glioma cell proliferation.
Materials and Methods
Antibodies, Material, and Enzymes
Themonoclonal mouse antibody directed against human p21Cip1/Waf1
(DCS60) as well as the polyclonal rabbit antibodies anti-human
p15INK4B, p16INK4A, p27Kip1, phospho-Rb (Ser795), phospho-Rb
(Ser807/811), and phospho-Cdk2 (Thr160) and the horseradish
peroxidase–labeled secondary antibodies, goat anti–mouse immuno-
globulin G, and goat anti-rabbit immunoglobulin G were obtained
from Cell Signaling Technology, Inc (Danvers, MA) and used ac-
cording to the manufacturer’s instructions. Monoclonal mouse anti–
human actin (C4) was purchased from ImmunO (dilution 1:10000;
MP Biomedicals, Inc, Aurora, OH). Polyclonal rabbit anti–human
phospho-SMAD-1(Ser463/465)/-5(Ser463/465)/-8(Ser426/428)
was from Chemicon International (Hampshire, UK; dilution 1:1000
for Western blot and 1:100 for immunofluorescence analysis). For
immunofluorescence analysis, goat anti–rabbit Cy3 (FluorolinkCy3,
CyDye; Amersham Pharmacia Biotech, Uppsala, Sweden; dilution
1:500) served as a secondary antibody. D-Luciferin potassium salt was
purchased from Synchem OHG (Felsberg/Altenburg, Germany).
Human recombinant BMP-7 was dissolved in 20-mM sodium acetate
trihydrate buffer with 5% (wt/vol) mannitol (pH 4.5), which also
served as control buffer throughout all experiments.
Cell Culture
The seven human glioblastoma–derived cell lines used were Gli36-
ΔEGFR, Gli36wt, and U87 MG (kind gifts of Dr David Louis, Mo-
lecular Neurooncology Laboratory, MGH, Boston, MA); U87ΔEGFR
(kind gift of Dr H.-J. Su Huang, Ludwig Institute for Cancer Re-
search, San Diego, CA); A172 and G55T2 (both kind gifts of Prof.
U. Schlegel, Department of Neurology, University Hospital Bonn,
Bonn, Germany); and U251 (kind gift of Prof. J. Hampl, Department
of Neurosurgery, University of Cologne, Cologne, Germany). All
cells were cultured in Dulbecco modified Eagle medium high glucose
(4.5 g/L) with L-glutamine and sodium pyruvate (PAA Laboratories
GmbH, Pasching, Austria) enriched with 10% (vol/vol) fetal calf serum
(FCS; PAA Laboratories GmbH), 100 U/ml penicillin and 100 μg/ml
streptomycin (P/S; PAA Laboratories GmbH) at 37°C in a 5% CO2/
95% air atmosphere. Gli36ΔEGFR and U87ΔEGFR cells were cul-
tured in the additional presence of the following selection antibiotics,
2 μg/ml puromycin (Sigma-Aldrich Chemie GmbH, München,
Germany) and 500 μg/ml G418 (Invitrogen Life Technologies,
Karlsruhe, Germany), respectively. All cell lines were cultured as mono-
layers and routinely passaged by trypsinization. The retrovirally trans-
duced cell lines Gli36ΔEGFR-LITG and U87ΔEGFR-LITG were
cultured under the same conditions.
Generation of Gli36ΔEGFR-LITG and U87ΔEGFR-LITG
Stable Cell Lines
The generation of the pBABE-LITG plasmid was based on the con-
struct pBABE-CITG (cytosine deaminase-IRES-tkgfp), which was gen-
erated by transferring the expression cassette CITG from pHSV-CITG
[24] into pBABE-puromycin. The luciferase gene, together with the
Kozak sequence, was amplified by polymerase chain reaction (PCR)
using the pTA-luc plasmid (Clontech-Takara Bio Europe, Saint-
Germain-en-Laye, France) as a template. The PCR amplicon, flanked
by 5′ XhoI and 3′ BglII restriction sites, was ligated into the pBABE-
ITG (IRES-tkgfp) backbone originated after XhoI/BglII digestion of
pBABE-CITG. Retroviral packaging was described previously [24].
RNA Isolation and Reverse Transcription–PCR
Total RNA was isolated from human glioblastoma–derived cell lines
using RNeasy Plus Mini Kit and RNeasy Fibrous Tissue Mini Kit ac-
cording to the manufacturer’s instructions (Qiagen, Hilden, Germany).
Two micrograms of total RNA was reverse-transcribed according to
the manufacturer’s instructions (SuperScript II RNAse H− Reverse
Transcriptase; Invitrogen GmbH) using oligo d/T (Invitrogen GmbH)
as primers. PCR amplification was performed using the HotStarTaq
Master Mix Kit (Qiagen) with specific primers for TGF-β superfamily
signaling molecules (Table W1). Amplification of β-actin complemen-
tary DNAwas used as a positive control of each PCR. Negative controls
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were performed for each primer pair by omitting the corresponding
complementary DNA template. Numbers of cycles, specific annealing
temperatures, and extension times are provided in TableW1. PCR prod-
ucts were separated by electrophoresis in agarose gel (1% (wt/vol))
and visualized with ethidium bromide. Amplified fragments were iden-
tified by size and by sequencing after purification with QIAquick PCR
Purification Kit (Qiagen) according to the manufacturer’s instructions.
Primer pairs were generated by using PerlPrimer v1.1.10 Software (free
software http://perlprimer.sourceforge.net). The origin of primer pairs,
which were not generated with this software, is given in Table W1.
Immunofluorescence
Immunofluorescence analysis was performed using standard proce-
dures. Cells were seeded at a density of 1.5 × 105/well in a 24-well plate
and incubated for 24 hours in corresponding medium containing only
1% (vol/vol) FCS. After treatment with human recombinant BMP-7
(500 ng/ml) or control buffer for 30, 60, and 90 minutes, cells were
fixed with 4% (vol/vol) paraformaldehyde/phosphate-buffered saline
(PBS) and permeabilized with 0.5% (vol/vol) Triton/PBS. Blocking
of unspecific binding sites was performed with 10% (wt/vol) BSA/
PBS containing 0.05% (vol/vol) Triton followed by incubation with
primary (rabbit anti–human phospho-SMAD-1/-5/-8) and secondary
antibodies (goat anti–rabbit Cy3). Cells were mounted with AquaPoly/
Mount (Polysciences, Inc, Warrington, PA), and fluorescence was moni-
tored with a Zeiss Axiovert 135 fluorescence microscope (Carl Zeiss,
Heidenheim, Germany). Photographs were prepared using an INTAS
digital camera (Göttingen, Germany).
Cell Cycle Analysis
Cells were seeded at a density of 3.6 × 105 cells/6-cm dish and
incubated for 24 hours in medium containing only 1% (vol/vol)
FCS. After 24 hours of stimulation with human recombinant BMP-7
(500 ng/ml) or control buffer, all cells were collected, washed twice in
PBS, and frozen in EtOH. Cellular DNA was stained with propidium
iodide (Sigma-Aldrich Chemie GmbH) according to the methods
described by Vindelov et al. [25–28]. The cellular DNA content
was analyzed by flow cytometry (FACSCalibur; Becton Dickinson,
Heidelberg, Germany). All experiments were done in triplicate.
Cell Proliferation
To analyze the effects of BMP-7 on Gli36ΔEGFR-LITG cell prolif-
eration, cells were seeded at a density of 3 × 104 cells/well in a 24-well
plate and incubated in medium containing 1% (vol/vol) FCS. After
24 hours, control cells were harvested and counted before starting
the cytokine treatment (0 hour). Cells were stimulated with BMP-7
(500 ng/ml) or control buffer for 24, 48, 72, and 96 hours. Fresh
cytokine or control buffer was added to corresponding wells 48 hours
after initial stimulation because recombinant BMP-7 was not stable
over the time in cell culture medium. After stimulation, cells were
trypsinized and counted using cell Fast-Read 102 counting chambers
(Biosigma s.r.l., Cona, Italy), and dead cells were visualized by Trypan
blue staining (0.2% [vol/vol]; bioWhittaker, Inc, Walkersville, MD).
All experiments were performed six times.
In addition, cell proliferation was monitored by bioluminescence
imaging of luciferase activity using an IVIS200 optical imaging sys-
tem (Xenogen Corp). Gli36ΔEGFR-LITG cells were seeded and
cultured as described above followed by treatment with BMP-7
(500 ng/ml) or control buffer for 48 hours. Bioluminescence was
detected 8 minutes after adding D-luciferin (80 μg/well in 40 μl of
PBS). Images were acquired at standard camera settings for bio-
luminescence imaging with exposure times of 5 seconds to 1 minute.
Data evaluation based on ROI (region of interest) analysis of bio-
luminescence images was performed by the use of Living Image Soft-
ware version 2.50 (Xenogen Corp) to determine total flux values
(photons/sec). All experiments were done in triplicate.
Caspase-3/-7 Activity Assay
Caspase-3/-7 activity was determined using the Caspase-Glo 3/7
Assay (Promega, Mannheim, Germany) according to the manufac-
turer’s instructions. Gli36ΔEGFR-LITG cells were seeded at a den-
sity of 5 × 103 cells/well in a 96-well and incubated in medium
containing 1% (vol/vol) FCS for 24 hours. Cells were treated with
BMP-7 (500 ng/ml) or control buffer for 24, 48, and 96 hours. Fresh
cytokine or control buffer was added to corresponding wells 48 hours
after initial stimulation. After treatment, 100 μl of Caspase-Glo Re-
agent was added to each well and incubated for 1 hour at 37°C.
Luminescence was monitored using a Mithras LB 940 plate reader
(Berthold Technologies, Bad Wildbad, Germany). All experiments
were performed in triplicate.
Preparation of Cell Lysates and Immunoblot Analysis
Cells were seeded at a density of 1.5 × 106 cells/6-cm-diameter dish
in medium containing 1% (vol/vol) FCS and cultured in the absence/
presence of human recombinant BMP-7 (500 ng/ml) for 1, 6, 24, and
48 hours. Cells were collected by scraping, and lysates were prepared
as described previously [29] in the presence of 1 mM sodium ortho-
vanadate (Sigma-Aldrich Chemie GmbH). Cell lysates, 50 μg, were
resolved by SDS-PAGE using Novex 14% (wt/vol) Tris-glycine gels
(Invitrogen GmbH). Proteins were transferred to Hybond-C Extra
(Amersham Biosciences, Braunschweig, Germany). Immunoblot analy-
sis was performed as described previously [29] in the presence of
50 mMNaF. All experiments were quantified by determining the signal
intensities using ImageJ 1.32j software (Wayne Rasband, National
Institutes of Health) and normalized to the signal intensities of the
β-actin loading control.
Animals
All animal experiments were in accordance with the National Insti-
tutes of Health guidelines and approved by the local animal care com-
mittee (Bezirksregierung Köln).
Gli36ΔEGFR-LITG cells (1 × 105) were implanted intracranially
into the striatum of immune-deficient mice (BALB/cA nude). For in-
travenous administration of recombinant BMP-7, microports (Style I
Catheter Microport for vascular access in mice; Braintree Scientific,
Inc, Braintree, MA) were implanted into the v. jugularis. Cell prolifera-
tion in vivo was monitored by bioluminescence imaging. After tumor
establishment (day 0) indicated by a total flux of 150,000 photons/sec,
mice were treated daily with the cytokine (100 μg/kg per day).
Bioluminescence Imaging of Luciferase Activity In Vivo
Analysis of luciferase gene expression was performed on an IVIS200
optical imaging system (Xenogen Corp). Bioluminescence imaging
was performed to monitor tumor growth. When tumors were estab-
lished, imaging was performed at day 0 (before treatment) to measure
the total flux of established tumors and to calculate the x-fold induction
of total flux at several time points after starting the therapy for each
animal individually. For bioluminescence detection, mice were injected
intraperitoneally with D-luciferin (4 mg/animal in 200 μl of PBS), and
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images were acquired 8 minutes after luciferin injection at standard
camera settings for bioluminescence imaging with exposure times of
10 seconds to 1 minute. Data evaluation based on ROI analysis of
bioluminescence images was performed by the use of Living Image
Software version 2.50 (Xenogen Corp) to determine total flux values
(photons/sec). Data were background subtracted after analyzing total
flux values of luciferase negative parts of mouse bodies with iden-
tical ROIs.
Statistics
Student’s t test was performedwith SigmaStat 3.0 (SPSS, Inc., Chicago,
IL) or with Microsoft Office Excel (Unterschleiβheim, Germany) using
a 2-tailed and heteroskedastic analysis. Level of significance was set at
P < .05.
Results
Expression of TGF-β Superfamily Signaling Molecules in
Different Human Glioblastoma–Derived Cell Lines
To characterize BMP-7 signaling in glioma in vitro and in vivo, we
used a panel of well-characterized human glioblastoma–derived cell
lines. In addition, two of the analyzed cell lines were retrovirally trans-
duced, and cell lines stably expressing the imaging gene cassette coding
for LITG (Gli36ΔEGFR-LITG and U87ΔEGFR-LITG) were gen-
erated. Analysis of transcripts expression for BMP-7, TGF-β1-3, their
relevant type I (Alk-1, -2, -3, -5, -6) and type II receptors (BMPRII,
ActrIIA, ActrIIB, TβR-II) as well as downstream signaling Smad pro-
teins (Smad-1, -2, -3, -4, -5, -6, -7, -8) was performed by RT-PCR
(Figure 1).
All cell lines expressed TGF-β1, Alk-2 and -5, BMPRII, ActrIIA,
ActrIIB, Smad-1, -3, -4, -5, and -8 messenger RNA (mRNA). TGF-β3
transcripts were not detected exclusively in A172 cells. Alk-1 mRNA
could only be observed in A172 cells, whereas Alk-5 transcripts were
absent in U251 and A172 cells. Gli36ΔEGFR-LITG cells expressed
nearly no TGF-β2 and only low levels of Alk-5 mRNA. Alk-6 transcripts
were nearly missing in Gli36ΔEGFR-LITG and absent in A172 cells.
U251 cells showed just weak amounts of TβR-II and Smad-7 mRNA.
Smad-6 transcripts were not detectable in Gli36ΔEGFR-LITG cells,
whereas Gli36wt cells expressed low amounts of these transcripts. U87
MG, G55T2, and A172 all lacked Smad-2 mRNA. Three cell lines
represented variable expression profiles of molecules of the intracellular
BMP-7 signaling. Gli36ΔEGFR-LITG cells expressed only low levels
of BMP-7 and Alk-6 and no Smad-6 mRNA, whereas A172 cells ex-
pressed high levels of BMP-7 and Smad-6 mRNA but lacked Alk-6,
and U87ΔEGFR-LITG cells did not express BMP-7 but expressed
Alk-6 and Smad-6 transcripts. Because of the different gene profiles,
we chose Gli36ΔEGFR-LITG, A172, and U87ΔEGFR-LITG cells to
further analyze BMP-7 signaling in vitro.
BMP-7 Downstream Signaling in Human Glioblastoma–
Derived Cell Lines
Before studying BMP-7 signaling effects in cell culture, we analyzed
if and how BMP-7 signals were transduced across the plasma mem-
brane of Gli36ΔEGFR-LITG, A172, and U87ΔEGFR-LITG cells. By
immunofluorescence, we analyzed phosphorylated regulatory Smad-1/
-5/-8 in cultured cells as well as by immunoblot analysis of cell lysates
after cells were treated with recombinant BMP-7 or control buffer
(Figure 2).
All three cell lines responded to BMP-7 treatment in cell culture.
Immunofluorescence staining of phosphorylated Smad-1/-5/-8 re-
vealed the highest levels of activated Smad proteins in A172 and
Gli36ΔEGFR-LITG cells already 30 and 60 minutes after cytokine
treatment, respectively (Figure 2A), whereas in U87ΔEGFR-LITG
cells, the highest levels of phosphorylated Smad proteins were attained
within 90 minutes of BMP-7 treatment (Figure 2A). The same results
were obtained after analyzing cell lysates derived from BMP-7 or con-
trol buffer–treated cells. Impressive amounts of activated regulatory
Smad proteins could only be detected in cells treated with BMP-7.
U87ΔEGFR-LITG cells responded slower (Figure 2B) to the cytokine
treatment when compared with the other cell lines (Figure 2, A and B).
Comparable amounts of phosphorylated Smad proteins were observed
24 hours after BMP-7 treatment (Figure 2B).
BMP-7 Induces G1 Cell Cycle Arrest in
Gli36ΔEGFR-LITG Cells
TGF-β and also BMPs have already been implicated in the regula-
tion of the cell cycle. Because all three analyzed cell lines responded to
BMP-7 stimulation, we further analyzed whether BMP-7 influences
the cell cycling of each of the tested cell lines. Therefore, we performed
cell cycle analysis 24 hours after BMP-7 stimulation (Figure 3). Plots
resulting from FACS analysis of Gli36ΔEGFR-LITG cells are pres-
ented exemplarily (Figure 3A). The differences obtained during cell
cycle analysis of all three cell lines were plotted inFigure 3B. We
can clearly demonstrate that BMP-7 treatment increased the number
of Gli36ΔEGFR-LITG cells being in G1 up to 15.6%, whereas cell
numbers in S and G2/M phases were significantly reduced of approxi-
mately 45% and 22.3%, respectively, when compared with control
buffer–treated cells (Figure 3B). Statistically significant results were
also obtained regarding cytokine-treated A172 cells, where increased
cell numbers in G1 and decreased cell numbers in S and G2/M phases
were observed, although the effect in these cells was weaker when
compared with stimulated Gli36ΔEGFR-LITG cells (Figure 3B).
However, U87ΔEGFR-LITG cells showed an opposite behavior after
cytokine treatment. The number of cells being in G1 phase was de-
creased, whereas the number of cells being in S and G2/M phases
Figure 1. mRNA expression profile of TGF-β superfamily signaling
molecules in various human glioblastoma–derived cell lines. Total
cellular RNA was subjected to RT-PCR analysis with specific primer
pairs, and amplicons were visualized by recording ethidium bromide
fluorescence. Names of analyzed cell lines are presented above
corresponding lanes (d = ΔEGFR).
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was increased, although these differences were not statistically signifi-
cant (Figure 3B).
Because of the highest sensitivity to BMP-7 treatment, we decided
to proceed to a detailed analysis of Gli36ΔEGFR-LITG cells.
BMP-7 Stimulation Decreases Gli36ΔEGFR-LITG
Cell Proliferation
In the further experiments, we analyzed the influence of BMP-7
on Gli36ΔEGFR-LITG cell proliferation and apoptosis (Figure 4).
In comparison to control buffer treated cells, numbers of proliferating
Gli36ΔEGFR-LITG cells decreased significantly 24 to 48 hours after
BMP-7 treatment (Figure 4A). However, cell numbers were increased
thereafter, suggesting that either BMP-7 has a basic effect on prolifera-
tion or that its stability in culture is timely limited (data not shown). To
test these hypothesis, we retreated the cells after 48 hours with fresh
cytokine and obtained a statistically significant growth inhibition with
up to 50% decrease of cell number within 96 hours of cytokine stimu-
lation when compared with control buffer–treated cells (Figure 4A),
thereby also suggesting that BMP-7 has a limited life span.
In addition, we also monitored cell proliferation in vitro by op-
tical imaging of luciferase activity 48 hours after BMP-7 or control
buffer treatment (Figure 4B). The total flux value obtained by bio-
luminescence imaging of cytokine-treated cells was considerably
lower compared with the total flux value of imaged control buffer–
treated cells.
To monitor apoptotic effects, we analyzed caspase-3/-7 activity
after BMP-7 and control buffer treatment (Figure 4C ). As before,
Gli36ΔEGFR-LITG cells were treated 48 hours after the initial
stimulation with fresh cytokine. Caspase activity was only weakly en-
hanced in BMP-7–treated cells after 24 hours. However, after 48 and
96 hours of BMP-7 stimulation, the response changed. We observed
increased caspase activity in control cells, whereas cytokine treatment
rescued cells from serum starvation. In comparison to control buffer–
treated cells, caspase activity was diminished up to 61.8% 96 hours
after BMP-7 stimulation.
BMP-7 Increased the Expression of CdkIs p21 and p27 and
Decreased the Phosphorylation of Cdk2 and pRb
The cell cycle analysis showed that most BMP-7–treated Gli36ΔEGFR-
LITG cells were arrested in the G1 phase of the cell cycle. To analyze
how BMP-7 signaling influences the proliferation of these cells, we in-
vestigated the effects of BMP-7 on the expression of CdkIs and down-
stream Cdk2 and Rb phosphorylation.
BMP-7 treatment did not alter the expression of p15INK4B at no
time point analyzed (Figure 5A). However, the expression of p21Cip1
was strongly and that of p27Kip1, to a lower extent, enhanced after
BMP-7 treatment (Figure 5A). This is clearly demonstrated after nor-
malization to the corresponding actin expression (Figure 5B). The
BMP-7 effect was much stronger on p21Cip1 expression, whose ex-
pression was increased up to 75% between 6 and 24 hours of cytokine
Figure 2. BMP-7 signal transduction monitored by detection of phosphorylated SMAD-1/-5/-8 (pSMAD-1/-5/-8) protein. Increasing
amounts of pSMAD-1/-5/-8 were analyzed either by immunofluorescence staining of cells 30, 60, and 90 minutes after treatment with
recombinant BMP-7 (500 ng/ml) (+) or control buffer (−) (d = ΔEGFR) (A) or by immunoblot analysis of cell lysates, obtained 1 and
24 hours after analogous cytokine treatment (B). Equally loaded protein amounts were demonstrated by detection of β-actin. Cells were
photographed at 400× magnification (bar = 100 μm).
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treatment compared with control cell lysates. During this cytokine
incubation period, p27Kip1 expression was also found to be elevated
up to 40% in comparison to corresponding controls (Figure 5A).
Furthermore, we analyzed the phosphorylation of Cdk2 at threonine
160, which is essential for the enzymatic activity of this cell cycle–
regulated kinase [30]. A striking reduction of Cdk2 phosphorylation
was observed already after 1 hour of BMP-7 treatment (Figure 5D).
Consequently, hypophosphorylation of Rb was detected after
24 hours of cytokine treatment. We could clearly demonstrate up to
32% less phosphorylation intensities at serine 807/811 as well as at
serine 795 (Figure 5C).
Bioluminescence Imaging of BMP-7–Triggered
Antiproliferative Effects In Vivo
By in vitro analysis, we know that BMP-7 affects the proliferation
of Gli36ΔEGFR-LITG cells. To analyze whether these findings have
implications for the growth of these tumor cells in vivo, we per-
formed bioluminescence imaging of luciferase activity in mice bear-
ing experimental gliomas undergoing BMP-7 treatment (Figure 6).
For this purpose, Gli36ΔEGFR-LITG cells were implanted intra-
cranially into nude mice, and after tumor formation, mice were treated
daily with recombinant BMP-7 or control buffer. Bioluminescence
imaging revealed altered growth of experimental gliomas in mice re-
ceiving BMP-7 therapy compared with untreated controls. On cyto-
kine treatment, the increase of luciferase activity we have detected up
to 10 days was dramatically lower than that detected in buffer-treated
control animals. Enzyme activity in control animals reached 29-fold
higher values compared with values obtained on day 0, whereas lucif-
erase activity in BMP-7–treated animals increased only 9.5-fold after
10 days of cytokine therapy (Figure 6A).
The differences in tumor growth in vivo were observed as soon as
3 days after BMP-7 treatment, when total flux values were 6.6-fold
higher in control animals compared with total flux values measured
in cytokine-treated animals. At this early time point, luciferase ac-
tivity was decreased up to 68% after BMP-7 stimulation in contrast
to buffer-treated control mice (Figure 6, A and B). Furthermore, by
immunohistochemical analysis of Ki67 and TUNEL-positive tumor
cells, we could show that decreased luciferase activity resulted from
diminished tumor cell proliferation and was not due to induced
apoptosis (Figures W1–W3).
Discussion
In this report, we provide evidence on the potential therapeutic ef-
fectiveness of the tumor-suppressive functions of BMP-7 in human
glioma–derived cells. Our experiments underline the crucial role
of the BMP-7/TGF-β signaling in the regulation of glioma cell pro-
liferation and, therefore, as possible and promising novel target in
glioma therapy.
In recent years, several reports have described a tumor-suppressive
function of BMP-7. The antitumorigenic effects of BMP-7 were
not only directed to tumor cells but also influenced tumor-initiating
cells, as it has been shown for human glioblastoma [22]. Tumor cells
of epithelial origin, like colon, androgen-insensitive prostate, anaplas-
tic thyroid, and breast carcinoma cells, respond to BMP-7 treatment
with growth suppression [16,17,19,20]. The increased expression of
p21Cip1/Waf1 that we have observed on treatment of glioma cells with
BMP-7 paralleled the observations made in BMP-7–treated anaplas-
tic thyroid carcinoma cells, which displayed increased expression of
p21Cip1/Waf1 and p27Kip1, followed by cell cycle arrest through inac-
tivation of Cdk2 and Cdk6 [17]. Estradiol-treated MCF-7 breast
cancer cells expressed augmented amounts of p21Cip1/Waf1 after
BMP-2 stimulation, which led to an inhibition of estradiol-induced
cyclin D1–associated kinase and Cdk2 activity [18]. In the case of
TGF-β, it has been shown that the cytokine upregulates the expression
of p15INK4B and p21Cip1/Waf1 and downregulates the expression of
c-myc, resulting in the inhibition of cell proliferation [12]. However,
BMP-7 did not show to have any effect on p15INK4B expression in
Gli36ΔEGFR-LITG cells. The same was true in BMP-7–treated
androgen-insensitive prostate carcinoma cells, where the cytokine did
not influence the expression of p15INK4B and c-myc, but increased the
expression of p21Cip1/Waf1, which inhibited Cdk2 activity [19]. There-
fore, BMP-7–mediated growth arrest might be transduced indepen-
dently from p15INK4B and differ from TGF-β–induced signaling
pathways. Nevertheless, besides p15INK4B, also other INK4A proteins,
like p16INK4A, p18INK4C, and p19INK4D, could be responsible for
arresting cells in G1 because they specifically inhibit Cdk4 and Cdk6.
We did not investigate p18INK4C or p19INK4D, but it has been shown
Figure 3. Cell cycle analysis of glioblastoma-derived cell lines. Cells
were treated for 24 hours with recombinant BMP-7 (500 ng/ml) or
control buffer and subjected to FACS analysis after propidium iodide
staining of cellular DNA. The y-axis denotes cell count, and the x-axis
represents DNA content. Each graph demonstrates a representative
of three independent experiments. Numbers of cells being in the
G1, S, and G2/M phases are presented in the right upper corner of
each graph and display the mean values of all experiments. (A)
Gli36ΔEGFR-LITG cells. (B) Cell cycle analysis of Gli36ΔEGFR-LITG,
A172, and U87ΔEGFR-LITG cells. Quantification of cell numbers be-
ing in G1, S, and G2/M phases after BMP-7 treatment is presented
in percent difference compared with numbers of control buffer–
treated cells (100%). Analyzed cell lines are depicted in the legend
of the graph.
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that Gli36ΔEGFR-LITG cells carry a p16-CDKN2A homozygous
deletion, thus we can exclude the involvement of p16INK4A in this
context [31].
Among all cell lines tested in our study, Gli36ΔEGFR-LITG cells
(and also Gli36wt cells) revealed the highest sensitivity to BMP-7
treatment resulting in growth arrest. The same was true for A172 cells,
yet the effect after cytokine treatment was weaker but still significant.
However, U87ΔEGFR-LITG cells responded slower to BMP-7 stimu-
lation and showed an opposite behavior during cell cycle analysis,
which was probably owing to increased apoptosis of cells rather than
growth arrest. We showed that these three cell lines represent different
expression profiles of BMP-7, Alk-6, Smad-6, and TGF-β2 transcripts,
which might explain their divergent responses to BMP-7 treatment.
Detailed analysis on protein functionality of BMP-7, its receptors
and downstream signaling molecules in these cell lines, needs to
be performed to clarify these effects. We propose that the differ-
ences between the cell lines used are not due to endogenous expres-
sion of BMP-7 but are due to downstream events. Interestingly,
Gli36ΔEGFR-LITG cells carry a missense mutation in both alleles
of the p53 gene, A172 cells carry only one mutated allele, and
U87ΔEGFR-LITG cells are p53 wild type [32–34]. Analyzing the
differences of expression and functionality of downstream signaling
events will be of great importance also regarding the clinical relevance
of glioblastoma therapy.
The antiproliferative effects of BMP-7 on Gli36ΔEGFR-LITG cells
presented in this study were detected when cells were cultured under
serum starvation (1% serum), whereas no efficient inhibition of pro-
liferation was achieved in the presence of regular growth medium
(10% serum; data not shown). In agreement with our findings, it has
been shown that, in the presence of 10% serum, BMP-7 does not
induce phosphorylation of Smad-1/-5 or expression of Id-1 in PC-3
cells [19]. The authors suggested that FCSmight either contain antago-
nists of BMP signals, such as Noggin and chordin, or induce their
expression. Besides antagonists of BMP signaling, also counteracting
cytokines, possibly present in the serum (not heat-inactivated), might
affect cell proliferation. However, the specific inhibition of TGF-β/
activin signaling through Alk-4, -5, and -7 in the presence of 10%
serum did not induce growth suppression by BMP-7 in PC-3 cells [19].
Figure 4. Analysis of cell proliferation and apoptosis in Gli36ΔEGFR-LITG cells. (A) Proliferation of cells was monitored after Trypan blue
exclusion of dead cells and counting viable cells at several time points before (0 hour) and after (24, 48, 72, and 96 hours) BMP-7 (500 ng/ml)
or control buffer treatment. All values are presented as the mean ± SD of six independent experiments. P values are depicted in the figure.
(B) Cell proliferation monitored by bioluminescence imaging. Luciferase activity was imaged 48 hours after BMP-7 (500 ng/ml) or control
buffer treatment, and this is presented as total flux values (photons/sec). All values are presented as the mean ± SD of three independent
experiments. P value is depicted in the figure (P ≤ .01). The image demonstrates a representative of three independent experiments.
(C) Caspase-3/-7 activity was assessed by homogeneous luminescent caspase assay, and this is presented as relative light units (RLUs).
All values are presented as the mean ± SD of three independent experiments. P values are depicted in the figure. Arrows indicate second
treatment of cells with recombinant BMP-7 (500 ng/ml) or control buffer 48 hours after initial cytokine treatment.
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The activity of caspase-3/-7 was clearly enhanced in buffer-treated
control cells compared with BMP-7–treated ones, suggesting that the
cytokine rescued Gli36ΔEGFR-LITG cells from serum starvation.
BMPs (BMP-7 and -2) have been shown to protect cells from
stress-induced apoptosis. In C4-2B cells but not in LNCaP cells, a
serum starvation–induced decrease of survivin was counteracted by
BMP-7, whereas expression levels of Bcl-xl, Bax, and XIAP remained
unaffected, pointing out antiapoptotic effects of BMPs [35].
However, taking into account that the proliferation of Gli36ΔEGFR-
LITG cells was impaired and cell cycle analysis displayed an arrest of
cells in the G1 phase, we conclude that BMP-7 induced cell cycle arrest
in the late G1 phase by upregulation of CdkI p21
Cip1/Waf1, which in-
hibited Cdk2 activation directly or by inhibiting Cdk4/Cdk6 in the
mid and late G1 phase.
Because in vitro analysis not always reflects exactly the in vivo situa-
tion, mouse experiments approaching in vivo conditions are essentially
Figure 5. Immunoblot analysis of Cdk inhibitors. Gli36ΔEGFR-LITG cell lysates were obtained after several time points of BMP-7 (500 ng/ml)
or control buffer treatment. (A) Protein expression of p15, p21, and p27. (B) Densitometric quantification of p21 protein expression after
normalization to β-actin protein expression. Differences of p21 protein amounts are presented as arbitrary units and resulted from quanti-
fication of three independent experiments (*P≤ .05). (C) Hypophosphorylation of Rb (Ser807/811, Ser795) could be detected 24 hours after
cytokine treatment. Quantification of Rb phosphorylation intensities of BMP-7–treated cells is presented as percent difference compared
with Rb phosphorylation intensities of control buffer–treated cells (100%) and resulted from quantification of two independent experiments.
(D) Decreased phosphorylation of Cdk2 (Thr160) was observed 1 hour after addition of BMP-7. Detection of β-actin protein served as a
loading control of each experiment, and this is presented for all corresponding Western blots.
Figure 6. In vivo bioluminescence imaging of luciferase activity in experimental gliomas. (A) Optical imaging of luciferase activity in BMP-
7–treated (lower panel) and buffer-treated (upper panel) nude mice 0, 3, 5, 7, and 10 days after the start of BMP-7/buffer treatment.
(B) Quantification of luciferase activity 3 days after the start of BMP-7 therapy (n = 6) compared with buffer-treated control mice (n = 6).
Luciferase activity at day 3 is presented as x-fold induction of total flux (photons/sec) normalized to total flux values at day 0 for BMP-7– and
buffer-treated mice, respectively.
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needed to prove cell culture results. Bioluminescence imaging represents
a useful and highly sensitive technique to study glioma cell prolifera-
tion and effects of antiproliferative compounds [36,37]. Shah et al.
[38] monitored both gene delivery and efficacy of TRAIL-induced
apoptosis in experimental brain tumors in vivo by dual-enzyme sub-
strate bioluminescence imaging. After intracranial implantation of
Gli36ΔEGFR-LITG cells, we were able to monitor the dynamics of
the antiproliferative effects of BMP-7 by optical imaging in vivo and
confirmed our experiments in cell culture. In fact, BMP-7 treatment
impaired the growth of experimental gliomas, clearly demonstrated by
bioluminescence imaging of luciferase activity that was diminished
up to 68% in BMP-7–treated animals compared with buffer-treated
control mice 3 days after starting the treatment (Figure W4). More
importantly, this antiproliferative effect of BMP-7 caused a blockage
of tumor growth up to 10 days, thus suggesting a potential use of
BMP-7 for glioma treatment. In vivo bioluminescence imaging of lucif-
erase activity together with magnetic resonance imaging and positron
emission tomography has been confirmed to be a powerful and quan-
titative tool for the assessment of antineoplastic therapies in living
animals [39–41]. These and other authors suggested that imaging lucif-
erase activity represents advantages over direct tumor volume mea-
surements because it provides a quantitative surrogate measure of the
metabolically active tumor cells excluding necrotic cells unable to emit
photons [38,39].
The divergent responses to BMP-7 of different cell lines that we
found in vitro seem to originate from varying downstream signaling
molecules and might also reflect the diversity of primary gliomas.
Screening the expression profiles and functionality of BMP-7/TGF-β
signaling molecules in primary gliomas could help to distinguish be-
tween responders and potential nonresponders. Regarding primary
gliomas, BMPs also inhibit the proliferation of cancer stem cells by in-
ducing differentiation of these cells [22]. More recently, opposite effects
of BMPs on cancer stem cells have been reported when the expression
pattern of BMPR is disturbed[23]. Supporting our findings in glioma
cell lines, the expression of downstream signaling molecules in cancer
stem cells also seem to determine BMP responsiveness, pointing out the
necessity of detailed screening studies in patients with gliomas.
In conclusion, we demonstrate that BMP-7 induces cell cycle arrest
at the G1/S checkpoint and, therefore, reduces the proliferation of
human glioma–derived Gli36ΔEGFR-LITG cells. BMP-7 treatment
increased the expression of CdkI p21Cip1, which led to a decreased level
of activated Cdk2 and hypophosphorylation of pRb. Taken together
with our in vivo analysis, we were able to noninvasively image and
quantify these antiproliferative effects of BMP-7 in vivo. These results
underline the potential role of targeting the BMP/TGF-β signaling
cascade for generating novel molecular approaches in cancer and espe-
cially glioblastoma therapy.
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Supplementary Materials and Methods
Immunohistochemistry
For the detection of proliferating and apoptotic cells in Gli36ΔEGFR-
LITG cells derived experimental gliomas, mouse brains of BMP-7–
treated and control animals were dissected after bioluminescence
analysis of accordant tumors. Before tumor dissection, mice were per-
fused with 4% paraformaldehyde. Afterward, brains were postfixed for
24 hours before paraffin embedding. Immunohistochemistry was carried
out using standard procedures on 4-μmsections. For the detection of pro-
liferating tumor cells, we used the Ki67 SP6 rabbit monoclonal primary
antibody (dilution 1:500, KI681C01; DCS Innovative Diagnostik-
SystemeGmbH&CoKG,Hamburg, Germany) and rabbit anti–mouse
biotin secondary antibody (dilution 1:200, E0413; DAKO GmbH,
Hamburg, Germany) plus biotin-avidin complex (Vectastain Elite ABC
Kit; Vector Laboratories, Ltd, Orton Southgate, Peterborough, UK) to
detect the primary antibody. DAB (3,3′-diaminobenzidine) substrate
was used to stain peroxidase activity (Vector Laboratories, Ltd).
For the detection of apoptotic cells, we used the DeadEnd Colori-
metric TUNEL System according to the manufactures’ instructions
(Promega GmbH). Positive controls for the detection of DNA frag-
mentation were performed using DNase I treatment and included in
each experiment. Counterstaining of cell nuclei was performed with
Mayer Hämalaun solution.
Analysis of Ki67 and TUNEL-positive cells was carried out as fol-
lows: We analyzed tumor sections of two sets of animals (n = 3).
One set was treated with BMP-7, and the other set was treated with
control buffer. Sections that were subjected to the analysis of prolifer-
ating and apoptotic cells were derived from four different parts of each
corresponding tumor (three tumors of each set of animals). After stain-
ing, sections were photographed at 200× magnification (bars = 50 μm),
and Ki67 or TUNEL-positive cells were counted per visual field (three
tumors of each set of animals ⇒ four sections per tumor ⇒ 1 visual
field per section⇒ 12 visual fields per set of animals). Statistical analysis
was performed using Student’s t test with Microsoft Office Excel. Sta-
tistical 4 tests were heteroskedastic and 2-tailed.
Table W1. Primer Pairs of TGF-β Superfamily Signaling Molecules.
Sequence Annealing Temperature (°C) Extension Time Cycles Amplicon Size (bp) Reference
BMP-7 For 3′ CACGCTACCACCATCGAGAG 5′ 58 41 sec 35 669 PerlPrimer v1.1.10 Software
Rev 3′ TTCATGTAGGAGTTCAGAGGGA 5′
Alk-2 For 3′ CTCCGAGTACCCCAGTGA 5′ 55 30 sec 35 457 PerlPrimer v1.1.10 Software
Rev 3′ CTGTGTTCCAGGGAAGGA 5′
Alk-3 For 3′ CAGAATCTGGATAGTATGCTTCATGGC 5′ 60 30 sec 35 418 PerlPrimer v1.1.10 Software
Rev 3′ GACAGCCATAGAAATGAGCAAAACCAGC 5′
Alk-6 For 3′ TGCGAAGTGCAGGAAAAT 5′ 55 30 sec 35 502 PerlPrimer v1.1.10 Software
Rev 3′ GGGATTCTCCAGGAGGAA 5′
BMPRII For 3′ CATTGGAGATCCCCAAGA 5′ 50 30 sec 35 382 PerlPrimer v1.1.10 Software
Rev 3′ ATATCGACCTCGGCCAAT 5′
ActrIIA For 3′ CTTCAAATCCAGTTACACCT 5′ 53 30 sec 35 490 PerlPrimer v1.1.10 Software
Rev 3′ CAGTTCATTCCAAGAGACCA 5′
ActrIIB For 3′ GATGACTTCAACTGCTACGA 5′ 55 37 sec 35 612 PerlPrimer v1.1.10 Software
Rev 3′ ATGTGATGATGTTCCCCTTGAG 5′
SMAD-1 For 3′ CATCAATCCCTACCACTATAAGAG 5′ 56 40 sec 35 534 PerlPrimer v1.1.10 Software
Rev 3′ GAAACCATCCACCAACACAC 5′
SMAD-5 For 3′ TCAACCCATACCACTATAAGAG 5′ 55 1 min 35 847 PerlPrimer v1.1.10 Software
Rev 3′ CTCATATACTGCCTCAAACCC 5′
SMAD-8 For 3′ CTCCCTCTTCTCCTTCACCA 5′ 57 1 min 35 871 PerlPrimer v1.1.10 Software
Rev 3′ CACCCTTTCCTATATGTCTCCT 5′
SMAD-4 For 3′ TCAATTCAAACCATCCAGCA 5′ 56 40 sec 35 665 PerlPrimer v1.1.10 Software
Rev 3′ GACCCAAACATCACCTTCAC 5′
TGF-β1 For 3′ TGGCGATACCTCAGCAACC 5′ 59 25 sec 35 405 Int J Cancer 2000;89:251–258
Rev 3′ CTCGTGGATCCACTTCCAG 5′
TGF-β2 For 3′ ATCCCGCCCACTTTCTACAGAC 5′ 61 35 sec 35 565 Int J Cancer 2000;89:251–258
Rev 3′ CATCCAAAGCACGCTTCTTCC 5′
TGF-β3 For 3′ TACTATGCCAACTTCTGCTC 5′ 55 32 sec 35 522 Int J Cancer 2000;89:251–258
Rev 3′ AACTTACCATCCCTTTCCTC 5′
Alk-5 For 3′ ACGGCGTTACAGTGTTTCTG 5′ 57 22 sec 35 358 Int J Cancer 2000;89:251–258
Rev 3′ GGTTGTGGCAGATATAGACC 5′
Alk-1 For 3′ CTCAGACACGACAACATCCT 5′ 57 31 sec 35 513 PerlPrimer v1.1.10 Software
Rev 3′ TATAGTCCTCCACGATGCCA 5′
Tβ-RII For 3′ AGCAACTGCAGCATCACCTC 5′ 58 42 sec 35 688 Int J Cancer 2000;89:251–258
Rev 3′ TGATGTCTGAGAAGATGTCC 5′
SMAD-2 For 3′ ATCCTAACAGAACTTCCGCC 5′ 57 31 sec 35 489 Int J Cancer 2000;89:251–258
Rev 3′ CTCAGCAAAAACTTCCCCAC 5′
SMAD-3 For 3′ AGAAGACGGGGCAGCTGGAC 5′ 57 31 sec 35 511 Int J Cancer 2000;89:251–258
Rev 3′ GACATCGGATTCGGGGATAG 5′
SMAD-6 For 3′ TGAATTCTCAGACGCCAGCA 5′ 55 30 sec 40 386 Biochem Biophys Res Commun
2001;287(1):47–55Rev 3′ GCTCGAAGTCGAACACCTT 5′
SMAD-7 For 3′ GCCCTCTCTGGATATCTTCT 5′ 55 30 sec 35 320 Biochem Biophys Res Commun
2001;287(1):47–55Rev 3′ GCTGCATAAACTCGTGGTCA 5′
β-actin For 3′ ATCTGGCACCACACCTTCTACAATGAGCTGCG 5′ 67 1 min 25 838 PerlPrimer v1.1.10 Software
Rev 3′ CGTCATACTCCTGCTTGCTGATCCACATCTGC 5′
Figure W1. Immunohistochemical analysis of Ki67 in experimental
gliomas. Mice brains were dissected 10 days after starting BMP-7
(100 μg/kg per day) or control buffer treatment (± BMP-7). Sections
(4 μm) of paraffin-embedded tissue were subjected to immunohisto-
chemical analysis of Ki67 expression. (A) Representative images of
mice brain sections are presented at 200× magnification (bars =
50 μm). (B) Ki67-positive cells were counted per visual field (VF);
meanswere calculated and plotted per set of animal (n= 3, P≤ .05).
Figure W2. TUNEL analysis in experimental gliomas. Mice brains were dissected 10 days after starting BMP-7 (100 μg/kg per day) or control
buffer treatment (± BMP-7). Sections (4 μm) of paraffin-embedded tissue were subjected to immunohistochemical analysis of TUNEL-
positive cells. (A) Representative images of mice brain sections are presented at 200× magnification (bars = 50 μm). Negative and positive
control sections (DNase I–treated) are included. (B) TUNEL-positive cells were counted per visual field (VF); means were calculated and
plotted per set of animals (n = 3, P = .78).
Figure W3. Numbers of viable and dead cells in the presence or
absence of BMP-7. Viable and dead cells were monitored after
Trypan blue exclusion and counted at several time points before
(0 hour) and after (24, 48, 72, and 96 hours) BMP-7 (500 ng/ml) or
control buffer treatment. All values are presented as the mean ±
SD of three independent experiments. P values are depicted in the
figure. (A) Numbers of dead cells in the absence or presence of
BMP-7. (B) Fractions of viable and dead cells in the presence or
absence of BMP-7.
Figure W4. Hematoxylin and eosin staining of experimental gliomas. Mice brains were dissected 10 days after starting BMP-7 (100 μg/kg
per day) or control buffer treatment (± BMP-7). Sections (4 μm) of paraffin-embedded tissue were subjected to hematoxylin and
eosin staining. Representative images of mice brain sections are presented at 12.5× and 200× magnifications (bars = 1000 μm and
100 μm, respectively).
